Pulmonary arterial hypertension: A review in pharmacotherapy

Bhaumik B. Patel, Ying Feng, Angela Cheng-Lai

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.

Original languageEnglish (US)
Pages (from-to)33-51
Number of pages19
JournalCardiology in review
Volume23
Issue number1
DOIs
StatePublished - Dec 14 2015

Keywords

  • Macitentan
  • Oral treprostinil
  • Riociguat
  • Six-minute walk distance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pulmonary arterial hypertension: A review in pharmacotherapy'. Together they form a unique fingerprint.

Cite this